On June 2, 2025 AimedBio reported it has successfully secured $38 million in a Pre-IPO funding round. The round was led by existing key investors—InterVest, DS Asset Management, Samsung Life Public Welfare Foundation, and SMB Investment Partners. Mirae Asset Securities joined as the sole new investor.
With the newly secured funding, AimedBio plans to accelerate the development of its next-generation ADC pipeline and advance preparations for global clinical trials. Following the licensing of its lead asset, AMB302, to U.S.-based Biohaven in December 2024, the company is now focusing on the preclinical development of the next candidates AMB303 and AMB304. At the same time, AimedBio aims to significantly expand its pipeline through next-generation ADC platform technologies.
Dr. Nam-Gu Her, CEO of AimedBio stated, "This Pre-IPO round closed earlier than expected, reflecting strong confidence from our existing shareholders. Mirae Asset Securities’ participation signals growing market confidence in AimedBio’s vision and potential."
"Based on our successful licensing deal to date, AimedBio is projected to achieve operating profitability for two consecutive half-years—the second half of 2024 and the first half of 2025. This is a significant milestone, as it demonstrates that the company has moved beyond potential to proving its ability to generate sustainable revenue," he added.
AimedBio also noted, "Additional technology licensing deals are expected within this year, and with the rapid expansion of our preclinical pipeline, we are set to accelerate high-growth momentum. Through the development of globally competitive ADC therapies, we aim to provide meaningful treatment options to patients and continuously enhance corporate value."
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
(Press release, AimedBio, JUN 2, 2025, View Source;s_keyword=&s_where=&start=0 [SID1234656917])